| Autor: |
Suleyman Nahit Sendur, Bahadir Koylu, Busra Firlatan, Hanife Seda Oguz, Selcuk Dagdelen, Tomris Erbas |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Journal of the Endocrine Society. 6:A491-A491 |
| ISSN: |
2472-1972 |
| DOI: |
10.1210/jendso/bvac150.1020 |
| Popis: |
Objectives Since the literature about giant (≥40 mm)pituitary somatotroph adenomas is limited to case reports, we aimed to summarize the characteristics of our giant somatotroph pituitary adenoma cohort and compare their clinical features and treatment responses with somatotroph macroadenomas. Materials and Methods This retrospective study included 16 patients (6 F/10 M) and 57 patients (29 F/28 M) with adenoma sizes ≥40 mm and 20-39 mm, respectively. The patients with Results In giant somatotroph adenomas group, mean value of the preoperative maximal diameter of adenoma was 44.8±10.1 mm (range 40-80 mm). Mean age at diagnosis was 31.8±12.6 years (range 11-55). Mean preoperative GH level was 127.4±257.1 ng/mL. The highest GH level was measured as 951 ng/mL in a female patient having a giant pituitary adenoma with a maximum diameter of 50 mm. Mean baseline IGF-1 level was 2.33±1. 04×ULN (upper limit of normal) for age and sex. Mean number of surgery was 2.4±1.5 (range 1-6) and mean number of treatment modalities applied to achieve hormonal remission postoperatively was 2.1±0.9 (range 1-3). After a mean duration of follow-up of 11.2±6.5 years (range 1-21 years), hormonal remission and partial control were achieved in nine and two patients, respectively. In the group with adenoma size Conclusion Giant somatotroph adenomas require an aggressive multimodal treatment approach and advanced care to achieve sustainable hormonal remission. Presentation: No date and time listed |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
